GSK strikes $1 billion licensing, development deal for potential hepatitis B treatment
GSK will pay some $1 billion to acquire rights to and commercialize an hepatitis B therapy from Johnson & Johnson in a deal announced Tuesday.
Read MorePosted by WRAL TechWire | Oct 31, 2023
GSK will pay some $1 billion to acquire rights to and commercialize an hepatitis B therapy from Johnson & Johnson in a deal announced Tuesday.
Read MorePosted by WRAL TechWire | Nov 12, 2021
Johnson & Johnson, the world’s largest health products company, is splitting up.
Read More